Swiss - Delayed Quote CHF

Idorsia Ltd (IDIA.SW)

Get top stock picks

5.12 +0.04 (+0.79%)

As of 9:18:33 AM GMT+2. Market Open.

Get top stock picks

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V

GlobeNewswire 28d ago

IDIA.SW
+0.79%
QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth

GlobeNewswire 1mo ago

IDIA.SW
+0.79%
Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call

GlobeNewswire 1mo ago

IDIA.SW
+0.79%
Is It Too Late To Consider Idorsia (SWX:IDIA) After Its Sharp 1-Year Surge

Simply Wall St. 3mo ago

IDIA.SW
+0.79%
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

GlobeNewswire 4mo ago

IDIA.SW
+0.79%
Why The Idorsia (SWX:IDIA) Narrative Is Resetting As Price Targets And Risks Evolve

Simply Wall St. 5mo ago

IDIA.SW
+0.79%
Idorsia appoints Roland Wandeler as Chief Executive Officer

GlobeNewswire 2mo ago

IDIA.SW
+0.79%
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

GlobeNewswire 4mo ago

IDIA.SW
+0.79%
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

GlobeNewswire 3mo ago

IDIA.SW
+0.79%
Idorsia announces the nomination of three candidates for election to the Board of Directors

GlobeNewswire 5mo ago

IDIA.SW
+0.79%
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

GlobeNewswire 4mo ago

IDIA.SW
+0.79%
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

GlobeNewswire 5mo ago

IDIA.SW
+0.79%

Yahoo Finance

U.S. markets open in 5h 55m

Idorsia Ltd (IDIA.SW)

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V

QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth

Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call

Is It Too Late To Consider Idorsia (SWX:IDIA) After Its Sharp 1-Year Surge

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Why The Idorsia (SWX:IDIA) Narrative Is Resetting As Price Targets And Risks Evolve

Idorsia appoints Roland Wandeler as Chief Executive Officer

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder